Literature DB >> 24388027

Drug-induced liver injury.

Michael D Leise1, John J Poterucha2, Jayant A Talwalkar2.   

Abstract

Drug hepatoxicity can be nonidiosyncratic (predictable), as in the case of acetaminophen, or idiosyncratic (unpredictable). This review article focuses primarily on idiosyncratic drug-induced liver injury (DILI). New epidemiologic data suggest that approximately 20 new cases of DILI per 100,000 persons occur each year. Idiosyncratic DILI accounts for 11% of the cases of acute liver failure in the United States. Risk factors for DILI include medication dose, drug lipophilicity, and extent of hepatic metabolism. There is mixed evidence to support the role of host factors such as age, sex, and chronic liver disease in the development of DILI. For specific drugs, a genetic predisposition appears to be a risk factor for DILI. Suspected cases of idiosyncratic DILI should be categorized as hepatitic, cholestatic, or mixed on the basis of the degree/ratio of abnormalities in the alanine aminotransferase and alkaline phosphatase. A careful evaluation for other causes of liver disease should be performed, though a liver biopsy is rarely needed. There is evidence that some patients with DILI may actually have hepatitis E and this diagnosis should be considered. Amoxicillin/clavulanate isoniazid, and nonsteroidal anti-inflammatory drugs are among the most common causes of DILI. Drug discontinuation or dechallenge should lead to an improvement in liver biochemistries in most patients, though a bilirubin value of more than 3 g/dL is associated with mortality of at least 10%. New biomarkers for DILI using proteomics and micro RNA appear promising but require further study. New studies on drugs with potential for causing DILI are reviewed herein, including tumor necrosis factor-alpha antagonists, fluoroquinolones, tyrosine kinase inhibitors, statins, and supplements. PubMed was used with search terms of drug induced liver injury OR DILI with filter settings of "English language" and "humans" and custom date range of "January 1, 2000." The authors also manually searched bibliographies from key references and included seminal references before the year 2000.
Copyright © 2014 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  AIH; ALF; ALT; CNS; DI-AIH; DILI; DILIN; Drug Induced Liver Injury Network; FDA; Food and Drug Administration; HDS; HEV; HLA; IV; LTx; N-Acetylcysteine; NAC; NAFLD; TNF; ULN; acute liver failure; alanine aminotransferase; autoimmunelike hepatitis; central nervous system; drug-induced autoimmunelike hepatitis; drug-induced liver injury; hepatitis E virus; herbal and dietary supplement; human leukocyte antigen; intravenous; liver transplantation; miRNA; micro RNA; nonalcoholic fatty liver disease; tumor necrosis factor; upper limit of normal

Mesh:

Substances:

Year:  2014        PMID: 24388027     DOI: 10.1016/j.mayocp.2013.09.016

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  101 in total

Review 1.  Hepatotoxicity Associated with the Use of Anti-TNF-α Agents.

Authors:  Joshua B French; Maurizio Bonacini; Marwan Ghabril; David Foureau; Herbert L Bonkovsky
Journal:  Drug Saf       Date:  2016-03       Impact factor: 5.606

2.  Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.

Authors:  Kevin R MacKenzie; Mingkun Zhao; Mercedes Barzi; Jin Wang; Karl-Dimiter Bissig; Mirjana Maletic-Savatic; Sung Yun Jung; Feng Li
Journal:  Eur J Pharm Sci       Date:  2020-07-23       Impact factor: 4.384

3.  An Unusual Case of Acute Liver Failure Caused by Adjuvant Oral Tegafur-Uracil with Folinate Therapy for Colon Cancer Patient: a Case Report.

Authors:  Masatsugu Hiraki; Toshiya Tanaka; Futa Koga; Akimasa Saito; Noriko Oza; Osamu Ikeda; Tatsuya Manabe; Atsushi Miyoshi; Kenji Kitahara; Seiji Sato; Hirokazu Noshiro
Journal:  J Gastrointest Cancer       Date:  2020-03

Review 4.  Role of miRNA and its potential as a novel diagnostic biomarker in drug-induced liver injury.

Authors:  Sukumaran Sanjay; Chandrashekaran Girish
Journal:  Eur J Clin Pharmacol       Date:  2016-12-27       Impact factor: 2.953

5.  Liuweiwuling tablets attenuate acetaminophen-induced acute liver injury and promote liver regeneration in mice.

Authors:  Yan-Chang Lei; Wen Li; Pan Luo
Journal:  World J Gastroenterol       Date:  2015-07-14       Impact factor: 5.742

Review 6.  N-acetylcysteine for non-paracetamol drug-induced liver injury: a systematic review.

Authors:  Mohamed Farouk Chughlay; Nicole Kramer; C Wendy Spearman; Mahmoud Werfalli; Karen Cohen
Journal:  Br J Clin Pharmacol       Date:  2016-03-02       Impact factor: 4.335

Review 7.  In vitro testing for diagnosis of idiosyncratic adverse drug reactions: Implications for pathophysiology.

Authors:  Abdelbaset A Elzagallaai; Michael J Rieder
Journal:  Br J Clin Pharmacol       Date:  2015-06-01       Impact factor: 4.335

8.  Optimization of decision support tool using medication regimens to assess rehospitalization risks.

Authors:  C H Olson; M Dierich; T Adam; B L Westra
Journal:  Appl Clin Inform       Date:  2014-08-27       Impact factor: 2.342

9.  Effect of a Common Genetic Variant (p.V444A) in the Bile Salt Export Pump on the Inhibition of Bile Acid Transport by Cholestatic Medications.

Authors:  Izna Ali; Seher Khalid; Bruno Stieger; Kim L R Brouwer
Journal:  Mol Pharm       Date:  2019-01-25       Impact factor: 4.939

10.  Acetaminophen-Induced Liver Injury Alters Expression and Activities of Cytochrome P450 Enzymes in an Age-Dependent Manner in Mouse Liver.

Authors:  Yifan Bao; Pei Wang; Xueyan Shao; Junjie Zhu; Jingcheng Xiao; Jian Shi; Lirong Zhang; Hao-Jie Zhu; Xiaochao Ma; José E Manautou; Xiao-Bo Zhong
Journal:  Drug Metab Dispos       Date:  2020-02-24       Impact factor: 3.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.